These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1644 related articles for article (PubMed ID: 32706953)
21. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial. Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM; Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478 [TBL] [Abstract][Full Text] [Related]
22. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin. Cipriani A; Zorzi A; Ceccato D; Capone F; Parolin M; Donato F; Fioretto P; Pesavento R; Previato L; Maffei P; Saller A; Avogaro A; Sarais C; Gregori D; Iliceto S; Vettor R Int J Cardiol; 2020 Oct; 316():280-284. PubMed ID: 32439366 [TBL] [Abstract][Full Text] [Related]
23. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. Cao B; Wang Y; Wen D; Liu W; Wang J; Fan G; Ruan L; Song B; Cai Y; Wei M; Li X; Xia J; Chen N; Xiang J; Yu T; Bai T; Xie X; Zhang L; Li C; Yuan Y; Chen H; Li H; Huang H; Tu S; Gong F; Liu Y; Wei Y; Dong C; Zhou F; Gu X; Xu J; Liu Z; Zhang Y; Li H; Shang L; Wang K; Li K; Zhou X; Dong X; Qu Z; Lu S; Hu X; Ruan S; Luo S; Wu J; Peng L; Cheng F; Pan L; Zou J; Jia C; Wang J; Liu X; Wang S; Wu X; Ge Q; He J; Zhan H; Qiu F; Guo L; Huang C; Jaki T; Hayden FG; Horby PW; Zhang D; Wang C N Engl J Med; 2020 May; 382(19):1787-1799. PubMed ID: 32187464 [TBL] [Abstract][Full Text] [Related]
24. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. Pani A; Lauriola M; Romandini A; Scaglione F Int J Antimicrob Agents; 2020 Aug; 56(2):106053. PubMed ID: 32534189 [TBL] [Abstract][Full Text] [Related]
25. Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study. Kalligeros M; Shehadeh F; Atalla E; Mylona EK; Aung S; Pandita A; Larkin J; Sanchez M; Touzard-Romo F; Brotherton A; Shah R; Cunha CB; Mylonakis E J Glob Antimicrob Resist; 2020 Sep; 22():842-844. PubMed ID: 32763357 [TBL] [Abstract][Full Text] [Related]
26. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM; JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939 [TBL] [Abstract][Full Text] [Related]
27. RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Gautret P; Lagier JC; Parola P; Hoang VT; Meddeb L; Mailhe M; Doudier B; Courjon J; Giordanengo V; Vieira VE; Tissot Dupont H; Honoré S; Colson P; Chabrière E; La Scola B; Rolain JM; Brouqui P; Raoult D Int J Antimicrob Agents; 2020 Jul; 56(1):105949. PubMed ID: 32205204 [TBL] [Abstract][Full Text] [Related]
28. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. Tang W; Cao Z; Han M; Wang Z; Chen J; Sun W; Wu Y; Xiao W; Liu S; Chen E; Chen W; Wang X; Yang J; Lin J; Zhao Q; Yan Y; Xie Z; Li D; Yang Y; Liu L; Qu J; Ning G; Shi G; Xie Q BMJ; 2020 May; 369():m1849. PubMed ID: 32409561 [TBL] [Abstract][Full Text] [Related]
29. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. Hernandez AV; Roman YM; Pasupuleti V; Barboza JJ; White CM Ann Intern Med; 2020 Aug; 173(4):287-296. PubMed ID: 32459529 [TBL] [Abstract][Full Text] [Related]
30. Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients. Carlucci PM; Ahuja T; Petrilli C; Rajagopalan H; Jones S; Rahimian J J Med Microbiol; 2020 Oct; 69(10):1228-1234. PubMed ID: 32930657 [No Abstract] [Full Text] [Related]
31. Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin? Li C; Cheng G Front Immunol; 2020; 11():1969. PubMed ID: 32849658 [TBL] [Abstract][Full Text] [Related]
32. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial. González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063 [TBL] [Abstract][Full Text] [Related]
33. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. ; Horby P; Mafham M; Linsell L; Bell JL; Staplin N; Emberson JR; Wiselka M; Ustianowski A; Elmahi E; Prudon B; Whitehouse T; Felton T; Williams J; Faccenda J; Underwood J; Baillie JK; Chappell LC; Faust SN; Jaki T; Jeffery K; Lim WS; Montgomery A; Rowan K; Tarning J; Watson JA; White NJ; Juszczak E; Haynes R; Landray MJ N Engl J Med; 2020 Nov; 383(21):2030-2040. PubMed ID: 33031652 [TBL] [Abstract][Full Text] [Related]
34. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Chorin E; Wadhwani L; Magnani S; Dai M; Shulman E; Nadeau-Routhier C; Knotts R; Bar-Cohen R; Kogan E; Barbhaiya C; Aizer A; Holmes D; Bernstein S; Spinelli M; Park DS; Stefano C; Chinitz LA; Jankelson L Heart Rhythm; 2020 Sep; 17(9):1425-1433. PubMed ID: 32407884 [TBL] [Abstract][Full Text] [Related]
35. The COVIRL-001 Trial: A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the treatment of non- critical, SARS-CoV-2 PCR-positive population not requiring immediate resuscitation or ventilation but who have evidence of clinical decline: A structured summary of a study protocol for a randomised controlled trial. Feeney E; Wallace D; Cotter A; Tinago W; McCarthy C; Keane D; Hussain R; Alvarez Barco E; Doran P; Mallon P Trials; 2020 May; 21(1):430. PubMed ID: 32450915 [No Abstract] [Full Text] [Related]
36. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial. McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067 [TBL] [Abstract][Full Text] [Related]
37. Cardiovascular Safety of Azithromycin in Patients Hospitalized With COVID-19: A Prespecified Pooled Analysis of the COALITION I and COALITION II Randomized Clinical Trials. Furtado RHM; Barros E Silva PGM; Fonseca HAR; Serpa-Neto A; Correa TD; Guimarães HP; Pereira AJ; Olivato GB; Zampieri FG; Lisboa T; Junqueira DLM; Lapa MG; Monfardini F; Damiani LP; Echenique LS; Gebara OE; Hoffman Filho CR; Polanczyk CA; Rohde LE; Amazonas R; Machado FR; Avezum A; Azevedo LCP; Veiga VC; Rosa RG; Lopes RD; Cavalcanti AB; Berwanger O; Am J Cardiol; 2024 Mar; 214():18-24. PubMed ID: 38104755 [TBL] [Abstract][Full Text] [Related]
38. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. Bessière F; Roccia H; Delinière A; Charrière R; Chevalier P; Argaud L; Cour M JAMA Cardiol; 2020 Sep; 5(9):1067-1069. PubMed ID: 32936266 [TBL] [Abstract][Full Text] [Related]